VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Tuesday, December 30, 2025
Stock Comparison
Gilead Sciences, Inc. vs Johnson & Johnson
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Gilead Sciences, Inc.
GILD · NASDAQ Global Select Market
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Gilead Sciences, Inc.'s moat claims, evidence, and risks.
View GILD analysisJohnson & Johnson
JNJ · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Johnson & Johnson's moat claims, evidence, and risks.
View JNJ analysisComparison highlights
- Moat score gap: Gilead Sciences, Inc. leads (74 / 100 vs 61 / 100 for Johnson & Johnson).
- Segment focus: Gilead Sciences, Inc. has 5 segments (68.5% in HIV); Johnson & Johnson has 2 segments (64.1% in Innovative Medicine).
- Primary market structure: Oligopoly vs Competitive. Pricing power: Moderate vs Moderate.
- Moat breadth: Gilead Sciences, Inc. has 8 moat types across 3 domains; Johnson & Johnson has 5 across 3.
Primary market context
Gilead Sciences, Inc.
HIV
HIV treatment and prevention medicines (antiretroviral therapy and PrEP)
Global (U.S. and Europe are major markets)
Patients/prescribers; reimbursed by public and private payers; distributed via wholesalers and specialty pharmacies
Drug developer and marketing authorization holder
68.5%
Johnson & Johnson
Innovative Medicine
Branded prescription pharmaceuticals (biopharma)
Global
Wholesalers, hospitals, retailers, healthcare professionals, payers
Drug discovery, development, manufacturing, commercialization
64.1%
Side-by-side metrics
Moat coverage
Shared moat types
Gilead Sciences, Inc. strengths
Johnson & Johnson strengths
Segment mix
Gilead Sciences, Inc. segments
Full profile >HIV
Oligopoly
Oncology (Cell Therapy + Trodelvy)
Oligopoly
Liver Disease
Oligopoly
Veklury (Remdesivir)
Competitive
Other Products
Competitive
Johnson & Johnson segments
Full profile >Innovative Medicine
Competitive
MedTech
Oligopoly
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.